Guest guest Posted February 16, 2011 Report Share Posted February 16, 2011 Halozyme Therapeutics, Inc. and Roche announced the first patient received subcutaneous MabThera (Rituxan) (rituximab), in a Phase III registration trial using Enhanze ®. The current clinical trial is focused on patients with Follicular Non-Hodgkin's Lymphoma. This innovative technology may allow patients with NHL to receive MabThera in less than 10 minutes via a simple subcutaneous injection at their physician's office. How this will translate into CLL is unknown... Clinical Trial http://clinicaltrials.gov/ct2/show/NCT01200758?term=subcutaneous+mabthera & rcv_d=\ 14 ~chris CLLCANADA Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 17, 2011 Report Share Posted February 17, 2011 This sounds exactly like what I received 2 years ago and have not had chemo since.I was treated for both CLL and SLL and was given CHOP with Rituxan..... I have not had treatment since. Halozyme Therapeutics, Inc. and Roche announced the first patient received subcutaneous MabThera (Rituxan) (rituximab), in a Phase III registration trial using Enhanze ®. The current clinical trial is focused on patients with Follicular Non-Hodgkin's Lymphoma. This innovative technology may allow patients with NHL to receive MabThera in less than 10 minutes via a simple subcutaneous injection at their physician's office. How this will translate into CLL is unknown... Clinical Trial http://clinicaltrials.gov/ct2/show/NCT01200758?term= subcutaneous+mabthera & rcv_d=14 ~chris CLLCANADA Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.